Literature DB >> 6753893

Comparison of captopril and hydrochlorothiazide alone and in combination in mild to moderate essential hypertension.

M H Weinberger.   

Abstract

1 A placebo-controlled, randomised double-blind comparison of captopril 25 mg three times a day, hydrochlorothiazide 15 mg three times a day, and the combination was conducted in 207 patients with essential hypertension with supine diastolic blood pressures of 92-110 mm Hg. Significant decreases in blood pressure were seen in all three groups; the magnitude of decrease seen with captopril and hydrochlorothiazide was similar, while the combination produced an additive response greater (p less than 0.001) than captopril or hydrochlorothiazide alone. 2 The major side effect reported was a rash in fewer than 6% of patients taking captopril alone or in combination. Loss of taste or proteinuria was not observed. 3 The addition of captopril of hydrochlorothiazide blunted the hypokalaemia and hyperuricaemia observed with hydrochlorothiazide alone in addition to its antihypertensive synergy. These observations indicate that this relatively low dose of captopril is safe and efficacious in the treatment of mild to moderate hypertension alone and particularly when combined with a thiazide diuretic.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6753893      PMCID: PMC1427520          DOI: 10.1111/j.1365-2125.1982.tb02069.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  6 in total

1.  Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting-enzyme inhibitor (SQ 14,225, captopril) in hypertensive patients.

Authors:  D B Case; S A Atlas; J H Laragh; J E Sealey; P A Sullivan; D N McKinstry
Journal:  Prog Cardiovasc Dis       Date:  1978 Nov-Dec       Impact factor: 8.194

2.  Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man.

Authors:  H Gavras; H R Brunner; G A Turini; G R Kershaw; C P Tifft; S Cuttelod; I Gavras; R A Vukovich; D N McKinstry
Journal:  N Engl J Med       Date:  1978-05-04       Impact factor: 91.245

3.  Acute and chronic effects of the angiotensin-converting enzyme inhibitor captopril in severe hypertension.

Authors:  J Havelka; H Vetter; A Studer; P Greminger; T Lüscher; S Wollnik; W Siegenthaler; W Vetter
Journal:  Am J Cardiol       Date:  1982-04-21       Impact factor: 2.778

4.  Converting enzyme inhibition with an orally active compound in hypertensive man.

Authors:  E L Bravo; R C Tarazi
Journal:  Hypertension       Date:  1979 Jan-Feb       Impact factor: 10.190

5.  Role of sympathetic nervous system activity in the blood pressure response to long-term captopril therapy in severely hypertensive patients.

Authors:  M H Weinberger
Journal:  Am J Cardiol       Date:  1982-04-21       Impact factor: 2.778

6.  Clinical experience with captopril in the treatment of severe drug-resistant hypertension.

Authors:  A E Raine; J G Ledingham
Journal:  Am J Cardiol       Date:  1982-04-21       Impact factor: 2.778

  6 in total
  20 in total

1.  The effect of perindopril and hydrochlorothiazide alone and in combination on blood pressure and on the renin-angiotensin system in hypertensive subjects.

Authors:  C L Brown; C I Backhouse; J C Grippat; J P Santoni
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 2.  ACE inhibitors compared with thiazide diuretics as first-step antihypertensive therapy.

Authors:  I J Perry; D G Beevers
Journal:  Cardiovasc Drugs Ther       Date:  1989-12       Impact factor: 3.727

3.  Comparison of once and twice daily administration of captopril plus hydrochlorothiazide on 24 h blood pressure levels.

Authors:  L Poggi; B Vaisse; F Bernard; J Drivet-Perrin; R Sambuc
Journal:  Br J Clin Pharmacol       Date:  1987       Impact factor: 4.335

4.  Quinapril and blood lipids.

Authors:  P Koskinen; V Manninen; A Eisalo
Journal:  Br J Clin Pharmacol       Date:  1988-10       Impact factor: 4.335

Review 5.  Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  R N Brogden; P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

6.  Clinical acceptability of ACE inhibitor therapy in mild to moderate hypertension, a comparison between perindopril and enalapril.

Authors:  L Alcocer; C Campos; J H Bahena; A Nacaud; J Parra Carillo; C Calvo; C Weber; G Lerebours; L Mickalonis; M T Villahermosa
Journal:  Cardiovasc Drugs Ther       Date:  1995-06       Impact factor: 3.727

Review 7.  ACE inhibitors. Drug interactions of clinical significance.

Authors:  C Mignat; T Unger
Journal:  Drug Saf       Date:  1995-05       Impact factor: 5.606

8.  Evolution of diuretics and ACE inhibitors, their renal and antihypertensive actions--parallels and contrasts.

Authors:  A F Lant
Journal:  Br J Clin Pharmacol       Date:  1987       Impact factor: 4.335

9.  Captopril + hydrochlorothiazide 24 h ambulatory monitoring effects.

Authors:  R G Asmar; B M Pannier; C J Hugue; S Laurent; A Safavian; M E Safar
Journal:  Br J Clin Pharmacol       Date:  1987       Impact factor: 4.335

10.  Captopril in severe childhood hypertension--reversible anaemia with high dosage.

Authors:  H A Verhaaren; J Vande Walle; A Devloo-Blancquaert
Journal:  Eur J Pediatr       Date:  1986-04       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.